3Gimble JM , Robinson CE, W u XY, et al. Peroxisome proliferator activated receptor-γ activation by thiazokidinediones induces adipogenesis in bone marrow stromal cells. Molecular Pharmacology, 1996, (50) : 1087-1094.
4Bi YX, Sunada H,Yonezawa Y, et al. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm, 1999,25 (5) :571-581.
6Gomis R,Jones NP,Vallance SE,et al.Low-dose rosiglitazone enhance glycemic control when combined with sulphonylureas in type 2 diabetes[].Diabetologia.1999
7Kreider M,Miller E,Patel J.Rosiglitazone is safe and well tolerated as monotherapy or combination therapy in patients with type 2 diabetes mellitus (T2DM)[].Diabetes.1999
8Reiusset J,Auwerk J,Vidal H.Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone ( BRL 49563 ) in human adipocytes[].Biochemical and Biophysical Research Communications.1999
9Salzman A.Rosiglitazone is not associated with hepatotoxicity[].Diabetologia.1999
10Lebovitz HE,Patel J,Dole J,et al.Rosiglitazone (BRL 49653)monotherapy has significant glucose effect in type 2 diabetic patients[].Diabetologia.1998
